FibroGen, Inc (NASDAQ:FGEN) – Leerink Swann dropped their Q3 2017 earnings per share estimates for FibroGen in a note issued to investors on Tuesday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter, down from their prior estimate of ($0.22). Leerink Swann has a “Outperform” rating and a $82.00 price objective on the stock. Leerink Swann also issued estimates for FibroGen’s Q4 2017 earnings at ($0.69) EPS, FY2017 earnings at ($1.91) EPS, FY2018 earnings at ($2.88) EPS, FY2019 earnings at ($0.26) EPS, FY2020 earnings at $2.85 EPS and FY2021 earnings at $3.68 EPS.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The company had revenue of $29 million for the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Analysts Lower Earnings Estimates for FibroGen, Inc (FGEN)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.watchlistnews.com/leerink-swann-analysts-lower-earnings-estimates-for-fibrogen-inc-fgen/1466895.html.

A number of other research firms also recently issued reports on FGEN. Citigroup Inc. reissued a “buy” rating and issued a $48.00 target price on shares of FibroGen in a research report on Monday, June 26th. Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of FibroGen in a report on Tuesday. Finally, Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a report on Friday, July 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $60.17.

Shares of FibroGen (FGEN) opened at 43.65 on Thursday. FibroGen has a 52-week low of $15.60 and a 52-week high of $51.70. The stock’s 50 day moving average price is $34.38 and its 200-day moving average price is $28.07. The company’s market capitalization is $3.05 billion.

In other news, insider K Peony Yu sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $33.48, for a total value of $334,800.00. Following the completion of the transaction, the insider now directly owns 226,507 shares of the company’s stock, valued at $7,583,454.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Pat Cotroneo sold 28,346 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $33.97, for a total value of $962,913.62. Following the completion of the transaction, the vice president now directly owns 170,666 shares of the company’s stock, valued at $5,797,524.02. The disclosure for this sale can be found here. Insiders sold 404,974 shares of company stock valued at $12,515,438 over the last ninety days. Corporate insiders own 14.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in FibroGen during the first quarter worth approximately $111,000. SG Americas Securities LLC raised its stake in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares in the last quarter. Airain ltd acquired a new stake in FibroGen during the first quarter valued at about $236,000. BNP Paribas Arbitrage SA raised its stake in FibroGen by 589.1% in the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 6,327 shares in the last quarter. Finally, Parametric Portfolio Associates LLC acquired a new stake in FibroGen during the first quarter valued at about $249,000. 43.45% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.